Genetic Technologies Stock Current Valuation
| GTG Stock | 0.04 0.00 0.00% |
Valuation analysis of Genetic Technologies helps investors to measure Genetic Technologies' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Genetic Technologies' Begin Period Cash Flow is comparatively stable compared to the past year. Other Non Cash Items is likely to gain to about 1.5 M in 2024, despite the fact that Change In Cash is likely to grow to (6.5 M). Fundamental drivers impacting Genetic Technologies' valuation include:
Price Book 3.0984 | Enterprise Value 5.5 M | Enterprise Value Ebitda (4.37) | Price Sales 0.5863 | Enterprise Value Revenue 0.7091 |
Overvalued
Today
Please note that Genetic Technologies' price fluctuation is out of control at this time. Calculation of the real value of Genetic Technologies is based on 3 months time horizon. Increasing Genetic Technologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Genetic Technologies' intrinsic value may or may not be the same as its current market price of 0.04, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.039 | Real 0.0336 | Hype 0.04 |
The intrinsic value of Genetic Technologies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Genetic Technologies' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Genetic Technologies helps investors to forecast how Genetic stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Genetic Technologies more accurately as focusing exclusively on Genetic Technologies' fundamentals will not take into account other important factors: Genetic Technologies Company Current Valuation Analysis
Genetic Technologies' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Genetic Technologies Current Valuation | 5.53 M |
Most of Genetic Technologies' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genetic Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Genetic Technologies has a Current Valuation of 5.53 M. This is much higher than that of the Life Sciences Tools & Services sector and significantly higher than that of the Health Care industry. The current valuation for all Australia stocks is notably lower than that of the firm.
Genetic Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genetic Technologies' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Genetic Technologies could also be used in its relative valuation, which is a method of valuing Genetic Technologies by comparing valuation metrics of similar companies.Genetic Technologies is currently under evaluation in current valuation category among its peers.
Genetic Fundamentals
| Return On Equity | -1.85 | ||||
| Return On Asset | -0.63 | ||||
| Profit Margin | (1.24) % | ||||
| Operating Margin | (1.13) % | ||||
| Current Valuation | 5.53 M | ||||
| Shares Outstanding | 145.42 M | ||||
| Shares Owned By Insiders | 5.56 % | ||||
| Price To Book | 3.10 X | ||||
| Price To Sales | 0.59 X | ||||
| Revenue | 7.66 M | ||||
| Gross Profit | 6.01 M | ||||
| EBITDA | (11.43 M) | ||||
| Net Income | (12.02 M) | ||||
| Total Debt | 875.19 K | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (9.68 M) | ||||
| Target Price | 0.25 | ||||
| Number Of Employees | 55 | ||||
| Beta | 0.48 | ||||
| Market Capitalization | 5.67 M | ||||
| Total Asset | 6.19 M | ||||
| Retained Earnings | (166.38 M) | ||||
| Working Capital | (500.09 K) | ||||
| Net Asset | 6.19 M |
About Genetic Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genetic Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genetic Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genetic Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Genetic Stock Analysis
When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.